Services

Saturated Fatty Acid-Modified Oligonucleotides

Custom C4-C22 saturated fatty acid conjugation for DNA, RNA, ASO, siRNA, duplex RNA and specialty oligonucleotides, including post-synthetic conjugation, lipid modifier phosphoramidites, 3′ lipid supports, 2′-O-C16 and 2′-O-C22 nucleoside modifications, and mono- or multivalent lipid architectures.

C4-C22 Fatty Acids 5′ • 3′ • Internal Amidite • CPG • Conjugation 2′-O-C16 • 2′-O-C22 Mono • Di • Multivalent

A Focused Platform for Saturated Fatty Acid-Oligonucleotide Engineering

Bio-Synthesis supports saturated fatty acid-modified oligonucleotides across the C4-C22 range. The final architecture may be generated by post-synthetic fatty acid conjugation, direct lipid modifier phosphoramidite chemistry, a lipid-functionalized 3′ support, or a site-specific lipidated nucleoside such as 2′-O-C16 or 2′-O-C22.

These routes are chemically distinct. A post-conjugated palmitic acid oligo, a Palmitamido-C6/C7 modifier, and an internal 2′-O-C16 nucleotide all contain a C16 lipid component, but they differ in linkage, spacer, placement, synthesis route, purification behavior, and final molecular structure.

Design principle: choose the final molecular architecture first—chain length, position, linkage, spacer and valency—then select the synthesis or conjugation route that best matches that architecture.

Lipid delivery conjugation platforms
⌕ Click to Enlarge
Representative saturated fatty acid incorporation and conjugation routes
C4→22

Chain Length

Short-, medium-, long- and very-long-chain saturated fatty acids provide a broad hydrophobic design range.

5′/3′

Placement

5′, 3′ and selected internal positions can be addressed through different synthesis or conjugation strategies.

P(III)

Incorporation Chemistry

Modifier phosphoramidites, 3′ supports, modified nucleoside amidites and post-synthetic coupling are separate routes.

1×3×

Valency

Single-, dual- and multivalent saturated fatty acid architectures can be evaluated where the construct permits.

Select a Saturated Fatty Acid Chain Length

Use chain length as an engineering variable—not as a stand-alone predictor of biological performance. Hydrophobicity, linker, position, valency, oligonucleotide chemistry and formulation should be considered together.

C16 — Palmitic / Hexadecanoic Acid

A major saturated lipid design space with post-conjugation, direct modifier phosphoramidite, 3′ support, and site-specific 2′-O-C16 nucleoside options.

Available architecture
Potential positions

Design focus
    Manufacturing watch
      Representative C4 saturated fatty acid modification architectures showing internal modification, terminal 3-prime or 5-prime modification, 2-prime modification, and base modification.
      ⌕ Click to Enlarge
      C16 Palmitic / Hexadecanoic acid incorporation architectures — click to enlarge

      Compare C4-C22 Modifiers by Chemistry, Position and Architecture

      Use the filters to focus on direct phosphoramidite chemistry, 3′ support, post-synthetic conjugation, 2′-O lipidated nucleosides, or custom development. Select any fatty acid to expand its incorporation details without horizontal scrolling.

      Direct modifier chemistry

      Palmitamido-C6/C7-type phosphoramidites can provide defined terminal or internal C16 modifier architectures depending on reagent design.

      3′ support

      C16-functionalized solid support provides a defined 3′ lipid architecture.

      2′-O nucleoside library

      2′-O-C16-A, -C, -G and -U provide site-specific lipidated nucleotide placement.

      Post-conjugation

      5′, 3′, selected internal, branched, dual- and multivalent C16 architectures can be evaluated using suitable handles and linkers.

      Important: a post-conjugated palmitic-acid oligo, a Palmitamido-C7 modifier, and a 2′-O-C16 nucleotide are structurally different products and should be specified separately.

      Route selection is architecture-specific. Filter results identify practical chemistry families, but the exact reagent, linkage, spacer, position, deprotection conditions, purification method, scale and analytical package should be confirmed for each project. Availability labels do not imply that every reagent is routinely stocked; specialty and custom routes may require feasibility review.

      Four Ways to Introduce a Saturated Fatty Acid Architecture

      1

      Modifier Phosphoramidite

      A prebuilt lipid-containing modifier is coupled during automated oligonucleotide synthesis.

      Lipid AmiditeAutomated Synthesis5′ / Internal Product

      Examples: dodecanamido-, palmitamido-, and stearamido-type modifiers.

      2

      3′ Lipid CPG / Support

      A lipid-bearing solid support defines the lipid architecture at the 3′ terminus.

      Lipid SupportChain Growth3′ Lipid Oligo

      Examples: selected C12, C16, C18 and C22 support chemistries.

      3

      Post-Synthetic Conjugation

      The oligonucleotide is synthesized with a reactive handle first, then coupled to an activated fatty acid or lipid reagent.

      Reactive Oligo+Activated LipidConjugate

      Best fit: unusual chain lengths, custom linkers, internal handles, and multivalent constructs.

      4

      2′-O-Lipidated Nucleoside

      The saturated lipid is built into a modified A, C, G or U nucleoside phosphoramidite for site-specific placement.

      2′-O-C16/C22 MonomerSelected NucleotideSite-Specific Product

      Examples: 2′-O-C16-A/C/G/U and 2′-O-C22-A/C/G/U.

      Conjugation

      Oligo first, lipid second. Broadest flexibility for C4-C22, linkers, reactive handles, and multivalent architectures.

      Modifier Amidite

      Lipid introduced during synthesis. Good position control when a validated modifier fits the desired architecture.

      3′ Support

      3′ position defined from the start. Useful when a dedicated lipid-bearing CPG/support is available.

      2′-O Amidite

      Lipid at a defined nucleotide. Chemically distinct from a terminal fatty acid conjugate.

      What Can Be Conjugated—and Where Can the Saturated Lipid Be Placed?

      Saturated fatty acid placement on an oligonucleotide A publication-style oligonucleotide strand showing 5-prime terminal, internal, 3-prime terminal, and site-specific 2-prime-O lipidated nucleotide positions. 5′ 3′ 5′ lipid Internal lipid 2′O 2′-O-C16/C22 3′ lipid Placement and linkage define different molecular architectures
      5′ TerminalModifier phosphoramidite or post-synthetic conjugation.
      InternalInternal handle, modifier chemistry, or site-specific conjugation.
      3′ TerminalLipid-functionalized support or post-synthetic conjugation.
      2′-O Site-Specific2′-O-C16/C22 nucleoside phosphoramidite at a defined RNA nucleotide.
      Design note: the animation highlights placement options only. It does not imply that every saturated fatty acid is available through every incorporation route.

      Single-Stranded DNA

      Terminal or selected internal saturated fatty acid modification for probes, specialty DNA and surface/membrane studies.

      Positions: 5′, 3′, internal
      Routes: conjugation, modifier amidite, support

      Single-Stranded RNA

      Terminal, internal or nucleotide-specific lipidated RNA with attention to deprotection and RNA compatibility.

      Positions: 5′, 3′, internal, 2′-O
      Routes: all four routes

      ASO / Gapmer

      Hydrophobic conjugation can be coordinated with PS, MOE, cEt, LNA/BNA or other backbone/sugar designs.

      Positions: 5′, 3′, selected internal
      Focus: activity, protein binding, PK

      siRNA / Duplex RNA

      Lipid identity, strand, position, RNA modification pattern and duplex formation should be designed together.

      Positions: passenger/guide 5′ or 3′, internal
      Focus: RISC compatibility

      Aptamers

      Terminal or internal lipid anchors may support membrane association, cell-surface display or formulation studies.

      Focus: preserve folding and target binding

      Fluorescent / Imaging Oligos

      Lipid and fluorophore placement should be separated enough to reduce steric interference or quenching.

      Focus: spacer, optical performance

      Branched Oligos

      Branched scaffolds can support multiple saturated lipid groups at defined attachment points.

      Focus: valency, purification, homogeneity

      Custom Constructs

      Specialty DNA/RNA architectures, customer-supplied reagents and multicomponent constructs can be reviewed for feasibility.

      Focus: exact structure and route definition

      Where Saturated Fatty Acid-Modified Oligonucleotides Are Used

      Saturated fatty acid conjugation is used to tune the physical and biological behavior of oligonucleotides rather than to provide one universal delivery solution. Chain length, attachment position, linker, valency, sequence, backbone chemistry, and formulation should be evaluated together for the intended research objective.

      RNAi

      siRNA Delivery & Biodistribution Research

      Long-chain fatty acids such as C14, C16, C18, and C22 can be evaluated as hydrophobic conjugates for studying cellular association, circulation behavior, tissue exposure, and productive RNAi delivery.

      • Passenger- or guide-strand placement
      • Mono- versus multivalent lipidation
      • Compatibility with 2′-OMe, 2′-F, and PS patterns
      Antisense

      ASO & Gapmer Exposure Studies

      Saturated fatty acid conjugation can be combined with antisense backbones to investigate hydrophobicity, plasma-protein association, cellular uptake, and tissue-distribution behavior.

      • 5′ or 3′ terminal designs
      • Selected internal conjugation
      • PS and affinity-enhancing sugar chemistries
      Membrane

      Membrane Anchoring & Cell-Surface Display

      Longer saturated lipid chains can serve as hydrophobic anchors for studies involving membrane association, cell-surface presentation, liposome association, or lipid-containing model systems.

      • Terminal lipid anchors
      • Spacer-assisted presentation
      • DNA, RNA, aptamer, or probe formats
      SAR

      Chain-Length & Lipid-Valency Screening

      C4-C22 libraries allow systematic comparison of chain length while keeping the oligonucleotide sequence constant. Mono-, dual-, and multivalent constructs can further separate chain-length effects from lipid-density effects.

      • C4 → C22 chain-length series
      • 1× → 2× → multivalent series
      • 5′ versus 3′ versus internal placement
      Imaging

      Imaging, Tracking & Surface-Association Studies

      Saturated fatty acids can be combined with fluorophores or other reporters when the lipid, linker, and optical label are positioned to minimize steric interference or quenching.

      • Lipid + fluorophore constructs
      • Cell-association studies
      • Membrane localization research
      Formulation

      Nanoparticle & Lipid-Assembly Research

      Fatty acid-modified oligonucleotides can be evaluated as components of lipid-rich assemblies, model nanoparticles, or multicomponent delivery systems where hydrophobic anchoring is part of the experimental design.

      • Lipid-rich formulation studies
      • Surface presentation
      • Custom multicomponent constructs
      Application choice should not be separated from molecular architecture. A C16 terminal conjugate, a Palmitamido modifier, a 2′-O-C16 nucleotide, and a dual-C16 construct may all behave differently even though each contains a C16 lipid component.

      Single-, Dual- and Multivalent Saturated Fatty Acid Architectures

      Representative single, dual, and triple saturated fatty acid siRNA conjugates using myristic and docosanoic acid architectures
      ⌕ Click to Enlarge
      Representative mono-, di- and multivalent lipid-siRNA architectures

      Single Lipid

      C16—siRNA

      Useful baseline for evaluating lipid identity, strand and placement.

      Dual Lipid

      C16\ scaffold—siRNA C16/

      Tests whether increased lipid presentation changes physical or biological behavior.

      Multivalent

      C16 × 3+ → scaffold → oligo

      Advanced architecture requiring careful purification, solubility and analytical planning.

      Valency principle: more lipid does not automatically mean better delivery. Higher valency can change hydrophobicity, aggregation, protein interaction, chromatographic behavior, distribution and manufacturability.

      Where Should a Saturated Fatty Acid Be Placed on siRNA?

      For RNAi constructs, the lipid should be evaluated together with guide/passenger strand identity, 5′/3′ position, RNA stabilization pattern, linker and valency. Passenger-strand terminal placement is often a practical starting point, while guide-strand placement requires more careful RISC compatibility assessment.

      Passenger 3′

      Common starting architecture. Keeps the lipid away from the guide 5′ end and is convenient for terminal conjugation or support-based designs.

      Passenger 5′

      Useful alternative. Can align well with a terminal modifier amidite when that reagent matches the intended final linkage.

      Guide 3′

      Placement-sensitive. Can be explored but should be assessed for duplex behavior, Ago/RISC compatibility and potency.

      Guide 5′

      Highest caution. Bulky lipid placement near the guide 5′ end should not be treated as a routine default because of its role in Ago loading and recognition.

      Internal RNAi option: 2′-O-C16 or 2′-O-C22 modified nucleosides provide a different route to site-specific lipid placement and should be evaluated as distinct products from terminal C16/C22 conjugates.

      Common Saturated Fatty Acid-Oligonucleotide Problems

      Select a problem below. The panel updates with the observed result, likely causes, and practical design response—without requiring a long vertical navigation rail.

      Poor aqueous solubility or precipitation

      Long-chain or multivalent saturated fatty acid conjugates can self-associate during concentration, storage or reconstitution.

      Observed result
        Likely causes
          Design response

            Plan Purification and Release Around the Lipid Architecture

            Saturated fatty acid conjugates can behave very differently from unmodified oligonucleotides. Chain length, lipid number, linker and modality may alter synthesis efficiency, RP-HPLC retention, solubility, recovery, mass-spectrometric behavior and duplex handling.

            Identity

            Expected molecular mass and conjugate assignment by an appropriate mass method.

            Purity

            RP-HPLC or other fit-for-purpose chromatography adapted to hydrophobicity.

            Conjugation

            Assessment of product conversion and separation from unconjugated oligo or lipid-related species.

            Architecture

            Confirmation of intended lipid number, position and modifier type where analytically resolvable.

            Duplex

            Annealing and duplex assessment for siRNA or other duplex RNA designs when required.

            1

            Define Architecture

            Chain length • position • linker • valency • modality

            2

            Select Route

            Amidite • 3′ support • post-conjugation • 2′-O monomer

            3

            Purify & Characterize

            Hydrophobicity-aware purification • identity • purity • recovery

            4

            Deliver

            Formulation • handling • documentation • repeat manufacturing

            Design a Saturated Fatty Acid-Modified Oligonucleotide

            Share your sequence, oligonucleotide type, preferred C4-C22 lipid, target position, linker, desired valency, synthesis scale, purification grade and analytical requirements. If the exact route is not defined, Bio-Synthesis can review whether a modifier phosphoramidite, 3′ support, post-synthetic conjugation, or 2′-O-lipidated nucleoside is the most practical starting strategy.

            Helpful Design Information

            Lipid: C4-C22 or custom
            Position: 5′, 3′, internal, 2′-O
            Valency: 1×, 2×, multivalent
            Oligo: DNA, RNA, ASO, siRNA, duplex

            Related Platform

            For sterols, unsaturated fatty acids, phospholipids, PEG-lipids and steroid-derived modifiers, use the broader Lipid-Modified Oligonucleotide platform.

            Explore Lipid-Modified Oligos →

            Controlled Support from Lipid-Oligo Design Through Release

            QMS

            ISO-Supported Saturated Fatty Acid-Oligonucleotide Manufacturing

            Custom C4-C22 fatty acid-modified oligonucleotides are supported by controlled synthesis or conjugation, purification, analytical QC, documentation, traceability, and project-specific handling from feasibility through repeat manufacturing.

            ISO 9001:2015 Quality management system supporting documented synthesis, conjugation, purification, and release workflows.
            ISO 13485:2016 Medical-device quality framework supporting controlled documentation and traceable manufacturing processes.
            ISO 14001 Environmental management system supporting responsible laboratory and manufacturing operations.
            Analytical QC RP-HPLC or fit-for-purpose chromatography, MS identity confirmation, and project-specific analytical release testing.

            Saturated Fatty Acid-Oligonucleotide FAQ

            FAQ

            What is the difference between post-synthetic fatty acid conjugation and phosphoramidite incorporation?
             Post-synthetic conjugation first produces an oligonucleotide containing a reactive handle, then couples an activated saturated fatty acid or lipid reagent in a separate reaction. A lipid modifier phosphoramidite is coupled during automated synthesis. These routes can create different linkages and spacers even when the same carbon-chain length is used.
            Can saturated fatty acids be placed at the 5′, 3′ or internal position?
             Yes, depending on the architecture. 5′ and selected internal positions may be accessed with appropriate modifier phosphoramidites or post-conjugation handles; 3′ placement may use a lipid-functionalized support or post-conjugation; site-specific internal RNA placement may use 2′-O-lipidated nucleoside phosphoramidites.
            Are C16 palmitic acid conjugates and 2′-O-C16 RNA the same?
             No. A terminal or internal palmitic-acid conjugate, a Palmitamido-C6/C7 modifier, and a 2′-O-C16 nucleoside are different molecular architectures and should be specified separately.
            Can multiple saturated fatty acids be attached to one siRNA?
             Yes, mono-, dual- and multivalent architectures can be evaluated where the scaffold, handles, synthesis route and purification strategy support the design. Increasing valency also increases hydrophobic and manufacturing complexity.
            Which siRNA strand is usually considered first for lipid attachment?
             Passenger-strand terminal placement is often a practical starting point because it can reduce direct interference with guide-strand function. Guide-strand positions can also be explored, but they require more careful RISC and potency assessment.
            Why can long-chain fatty acid oligos be harder to purify?
             C16-C22 lipids and multivalent constructs can increase hydrophobic interaction with reverse-phase stationary phases, self-association and adsorption losses. Purification conditions may need to be adapted to the final architecture.

            Selected Literature for Fatty Acid-Oligonucleotide Design

            1. Wolfrum C, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotechnology. 2007;25:1149-1157.
            2. Biscans A, et al. The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo. Journal of Controlled Release. 2019;302:116-125.
            3. Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nature Biotechnology. 2017;35:238-248.
            4. Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Research. 2016;44(14):6518-6548.

            Scientific note: literature provides design context rather than a universal formula. Final chain length, linkage, placement, valency and delivery architecture should be evaluated in the context of the sequence and intended biological system.

            Why Choose Bio-Synthesis

            Trusted by biotech leaders worldwide for over 45 years of delivering high-quality, fast, and scalable synthetic biology solutions.